#151054

Anti-BCRABL [4C12]

Cat. #151054

Anti-BCRABL [4C12]

Cat. #: 151054

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: BCRABL

Class: Monoclonal

Application: IHC ; IF ; RIA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Queen Mary University of London

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-BCRABL [4C12]
  • Alternate name: Cyclin A2; Cyclin-A; CCN1; CCNA2
  • Clone: 4C12
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; RIA
  • Description: The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukemia (CML) and in a proportion of cases of acute lymphocytic leukemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9 and results in the production of a chimaeric BCR-ABL protein with enhanced kinase activity. These antibodies may be useful for studies of the oncogene and have potential diagnostic and prognostic applications.
  • Immunogen: BCR-ABL peptide
  • Isotype: IgG1
  • Myeloma used: P3X63Ag8.653

Target Details

  • Target: BCRABL
  • Target background: The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukemia (CML) and in a proportion of cases of acute lymphocytic leukemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9 and results in the production of a chimaeric BCR-ABL protein with enhanced kinase activity. These antibodies may be useful for studies of the oncogene and have potential diagnostic and prognostic applications.

Applications

  • Application: IHC ; IF ; RIA

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Dhut et al. 1990. Leukemia. 4(11):745-50. PMID: 2232885.
  • BCR-ABL and BCR proteins: biochemical characterization and localization.
  • Dhut et al. 1988. Oncogene. 3(5):561-6. PMID: 3078961.
  • Identification of two normal bcr gene products in the cytoplasm.
  • Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.
  • Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia.